Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H12N2O8.Ca.2Na.3H2O |
| Molecular Weight | 428.314 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O
InChI
InChIKey=XNLGJDRDNVYESE-UHFFFAOYSA-J
InChI=1S/C10H16N2O8.Ca.2Na.3H2O/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;;;;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;;;3*1H2/q;+2;2*+1;;;/p-4
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C10H15N2O8 |
| Molecular Weight | 291.2347 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | HO |
| Molecular Weight | 17.0073 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.webmd.com/balance/tc/chelation-therapy-topic-overview#1 | https://www.empowerpharmacy.com/drugs/edetate-disodium-injection.htmlhttp://umm.edu/health/medical/altmed/supplement/ethylenediaminetetraacetic-acidCurator's Comment: description was created based on several sources, including, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm
Sources: https://www.webmd.com/balance/tc/chelation-therapy-topic-overview#1 | https://www.empowerpharmacy.com/drugs/edetate-disodium-injection.htmlhttp://umm.edu/health/medical/altmed/supplement/ethylenediaminetetraacetic-acid
Curator's Comment: description was created based on several sources, including, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm
Edetic acid (EDTA) is a chelating agent. The U.S. Food and Drug Administration (FDA) approved edetic acid chelation therapy as a treatment for lead and heavy metal poisoning. Edetic acid in form of disodium salt was withdrawn from the market due to death resulting from hypocalcemia during chelation.
Originator
Sources: https://www.researchgate.net/publication/321552574_Ferdinand_Munz_EDTA_and_40_years_of_inventionshttps://www.google.com/patents/US2130505
Curator's Comment: Edetic acid was synthesized by Ferdinand Munz.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: divalent and trivalent metals |
|||
Target ID: CHEMBL2364029 |
18.3 null [pKd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Calcium disodium versenate Approved UseEdetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Launch Date-5.19523205E11 |
|||
| Curative | Calcium Disodium Versenate Approved UseEdetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Launch Date-5.19523205E11 |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Diagnostic | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
51 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3096624 |
1 g single, intramuscular dose: 1 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
EDETATE CALCIUM DISODIUM serum | Homo sapiens population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
60 min |
unknown, unknown |
EDETATE CALCIUM DISODIUM plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Co-administed with:: 2,3-dimercapto-1-propanol, i.v(3 mg/kg; 6/day; 5 days) Sources: |
unhealthy, 1-8 n = 130 Health Status: unhealthy Condition: Plumbism Age Group: 1-8 Sex: M+F Population Size: 130 Sources: |
Disc. AE: Acute renal failure... Other AEs: Nephrotoxicity... AEs leading to discontinuation/dose reduction: Acute renal failure (3%) Other AEs:Nephrotoxicity (mild, 13%) Sources: |
160 mg/kg single, intravenous Studied dose Dose: 160 mg/kg Route: intravenous Route: single Dose: 160 mg/kg Sources: Page: p.361 |
unhealthy, 49 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Multiple myeloma Age Group: 49 Sex: F Population Size: 1 Sources: Page: p.361 |
Disc. AE: Hypocalcemia... AEs leading to discontinuation/dose reduction: Hypocalcemia Sources: Page: p.361 |
400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
Disc. AE: Restlessness, Hypocalcemia... AEs leading to discontinuation/dose reduction: Restlessness Sources: Page: p.360Hypocalcemia |
400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache Sources: Page: p.360 |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Acute renal failure | 3% Disc. AE |
25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Co-administed with:: 2,3-dimercapto-1-propanol, i.v(3 mg/kg; 6/day; 5 days) Sources: |
unhealthy, 1-8 n = 130 Health Status: unhealthy Condition: Plumbism Age Group: 1-8 Sex: M+F Population Size: 130 Sources: |
| Nephrotoxicity | mild, 13% | 25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Co-administed with:: 2,3-dimercapto-1-propanol, i.v(3 mg/kg; 6/day; 5 days) Sources: |
unhealthy, 1-8 n = 130 Health Status: unhealthy Condition: Plumbism Age Group: 1-8 Sex: M+F Population Size: 130 Sources: |
| Hypocalcemia | Disc. AE | 160 mg/kg single, intravenous Studied dose Dose: 160 mg/kg Route: intravenous Route: single Dose: 160 mg/kg Sources: Page: p.361 |
unhealthy, 49 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Multiple myeloma Age Group: 49 Sex: F Population Size: 1 Sources: Page: p.361 |
| Hypocalcemia | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
| Restlessness | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
| Headache | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Inhibition of carcinogen induced c-Ha-ras and c-fos proto-oncogenes expression by dietary curcumin. | 2001 |
|
| Hydroxyl radical footprinting of proteins using metal ion complexes. | 2001 |
|
| Artificial iron-dependent proteases. | 2001 |
|
| Evaluation of Er:YAG laser and EDTAC on dentin adhesion of six endodontic sealers. | 2001 |
|
| Attachment of human gingival fibroblasts to periodontally involved root surface following scaling and/or etching procedures: a scanning electron microscopy study. | 2001 |
|
| Evaluation of copper availability to plants in copper-contaminated vineyard soils. | 2001 |
|
| Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture--primary culture cells markedly differ from fourth-passage cells. | 2001 |
|
| Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. | 2001 |
|
| Chromosomal mapping, gene structure and characterization of the human and murine RAB27B gene. | 2001 |
|
| Brain dystrophin-glycoprotein complex: persistent expression of beta-dystroglycan, impaired oligomerization of Dp71 and up-regulation of utrophins in animal models of muscular dystrophy. | 2001 |
|
| Chemical speciation used to assess [S,S']-ethylenediaminedisuccinic acid (EDDS) as a readily-biodegradable replacement for EDTA in radiochemical decontamination formulations. | 2001 Apr |
|
| Cloning and biochemical characterization of BglC, a beta-glucosidase from the cellulolytic actinomycete Thermobifida fusca. | 2001 Apr |
|
| Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. | 2001 Feb |
|
| Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. | 2001 Feb |
|
| Prolonged stability of endogenous cardiotrophin-1 in whole blood. | 2001 Feb |
|
| Characterization of a protease responsible for truncated actin increase in neutrophils of patients with Behçet's disease. | 2001 Feb |
|
| Microwave decalcification of human temporal bones. | 2001 Feb |
|
| Binding sites for progastrin-derived peptides in colonic crypts. | 2001 Feb |
|
| Estimation of glomerular filtration rate in cancer patients. | 2001 Feb |
|
| Localization of estrogen receptor beta protein expression in adult human bone. | 2001 Feb |
|
| Simultaneous determination of 226Ra and 210Pb in groundwater and soil samples by using the liquid scintillation counter-suspension gel method. | 2001 Feb |
|
| Pharmacological characterization and antithrombotic effect of agkistin, a platelet glycoprotein Ib antagonist. | 2001 Feb |
|
| Determination of glomerular filtration rate per unit renal volume using computerized tomography: correlation with conventional measures of total and divided renal function. | 2001 Feb |
|
| A high signal-to-noise Ca(2+) probe composed of a single green fluorescent protein. | 2001 Feb |
|
| Radiation sensitization of mammalian cells by metal chelators. | 2001 Feb |
|
| Influence of citrate and EDTA anticoagulants on plasma malondialdehyde concentrations estimated by high-performance liquid chromatography. | 2001 Feb 10 |
|
| Characterization of a model compound for the lysine tyrosylquinone cofactor of lysyl oxidase. | 2001 Feb 16 |
|
| Robustness of slope-intercept versus slope-only for measurement of glomerular filtration rate. | 2001 Jan |
|
| Phagocytic response of bovine polymorphonuclear leukocytes to different incubation conditions and following exposure to some effectors of phagocytosis and different anticoagulants in vitro. | 2001 Jan |
|
| Enhancement of jejunal absorption of conjugated bile acid by neurotensin in rats. | 2001 Jan |
|
| Differential inhibitory mechanism of Fe2+ and Fe3+ on contraction of ileal longitudinal smooth muscle. | 2001 Jan |
|
| Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. | 2001 Jan |
|
| Flow cytometric analysis of the human articular chondrocyte phenotype in vitro. | 2001 Jan |
|
| Comparison of lateral condensation and thermomechanically compacted warm alpha-phase gutta-percha with a single cone for obturating curved root canals. | 2001 Jan |
|
| Long-term preservation of chilled canine semen: effect of commercial and laboratory prepared extenders. | 2001 Jan 15 |
|
| The occurrence of internal (1 --> 5)-linked arabinofuranose and arabinopyranose residues in arabinogalactan side chains from soybean pectic substances. | 2001 Jan 15 |
|
| Environmental lead exposure and progressive renal insufficiency. | 2001 Jan 22 |
|
| Determination of metal complexes of ethylenediaminetetraacetate in the presence of organic matter by high-performance liquid chromatography. | 2001 Jan 5 |
|
| Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space. | 2001 Jan-Feb |
|
| Detection of bile duct leaks using MR cholangiography with mangfodipir trisodium (Teslascan). | 2001 Jan-Feb |
|
| [Plasma homocysteine measurement: a study of pre-analytical variation factors for conditions for total plasma homocysteine concentration]. | 2001 Jan-Feb |
|
| Mechanism of endothelin 1 production in the cochlea of rats. | 2001 Jan-Feb |
|
| Measurement of intact insulin-like growth factor-binding protein-3 in human plasma using a ligand immunofunctional assay. | 2001 Mar |
|
| Duration of sample storage dramatically alters expression of the human immunodeficiency virus coreceptors CXCR4 and CCR5. | 2001 Mar |
|
| Adherence of Giardia lamblia trophozoites to Int-407 human intestinal cells. | 2001 Mar |
|
| Kinetic modeling of liquid-phase adsorption of reactive dyes and metal ions on chitosan. | 2001 Mar |
|
| Two new modes of smooth muscle myosin regulation by the interaction between the two regulatory light chains, and by the S2 domain. | 2001 Mar |
|
| Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. | 2001 Mar |
|
| Effect of collagenase inhibitors on corneal haze after PRK. | 2001 Mar |
|
| Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. | 2001 Mar 15 |
Sample Use Guides
hypercalcemia: adults: 50 mg/kg/day (up to 3 g/day) administered by slow IV infusion. Frequency and duration of administration are quite variable, and should be determined based on the patient's serum calcium. Five consecutive daily doses may be administered, followed by 2 days without medication, repeating these courses as necessary to a total of 15 doses.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:05:40 UTC 2023
by
admin
on
Sat Dec 16 10:05:40 UTC 2023
|
| Record UNII |
5M645317UB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 172.120
Created by
admin on Sat Dec 16 10:05:40 UTC 2023 , Edited by admin on Sat Dec 16 10:05:40 UTC 2023
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Sat Dec 16 10:05:40 UTC 2023 , Edited by admin on Sat Dec 16 10:05:40 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5M645317UB
Created by
admin on Sat Dec 16 10:05:40 UTC 2023 , Edited by admin on Sat Dec 16 10:05:40 UTC 2023
|
PRIMARY | |||
|
76967923
Created by
admin on Sat Dec 16 10:05:40 UTC 2023 , Edited by admin on Sat Dec 16 10:05:40 UTC 2023
|
PRIMARY | |||
|
23411-34-9
Created by
admin on Sat Dec 16 10:05:40 UTC 2023 , Edited by admin on Sat Dec 16 10:05:40 UTC 2023
|
NON-SPECIFIC STOICHIOMETRY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |